Onyvax
Bradford
About Onyvax
Onyvax is developing new cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells. Onyvax's products specifically target cancer cells, increasing the likelihood that they will be effective while minimising side effects associated with many conventional treatments. These therapies can broadly be classed as therapeutic cancer vaccines.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $29.8M
- Funding stage: Late Stage Venture
- Last round: Series C (May 2006)
- Website: onyvax.com
- Phone: +44 20-8682-9494
Industries & Categories
Biotechnology, Health Care, Therapeutics
Canonical: https://fsome.com/organization/onyvax-1514414 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.